Fosaprepitant Dimeglumine
8 NDCs across 7 manufacturers|8 Generic,0 Brand
▸ More about this market▾ Less
The brand product was first FDA-approved on Jan 25, 2008, and the first generic was approved Jun 9, 2016. In 2024, Medicare Part D spent $527K on Fosaprepitant Dimeglumine across 2,730 claims for 720 beneficiaries.
Fosaprepitant Dimeglumine is available as 8 NDCs from 7 manufacturers (8 generic, 0 brand), with NADAC prices from $38.51 to $38.51 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
8
8G / 0B
Manufacturers
7
competing in market
Price Spread
$38.51 – $38.51
per EA
7d Activity
avg +0.0% WoW · of 8 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Hikma Pharmaceuticals USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Substance P/Neurokinin-1 Receptor Antagonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
7 manufacturers producing FOSAPREPITANT DIMEGLUMINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
FOSAPREPITANT 150 MG VIAL | $38.5080 per EA | — |
FOSAPREPITANT 150 MG VIAL | $38.5080 per EA | — |
FOSAPREPITANT 150 MG VIAL | $38.5080 per EA | — |
FOSAPREPITANT 150 MG VIAL | $38.5080 per EA | — |
FOSAPREPITANT 150 MG VIAL | $38.5080 per EA | — |
FOSAPREPITANT 150 MG VIAL | $38.5080 per EA | — |
FOSAPREPITANT 150 MG VIAL | $38.5080 per EA | — |
FOSAPREPITANT 150 MG VIAL | $38.5080 per EA | — |
Frequently Asked Questions
When did Fosaprepitant Dimeglumine become available as a generic?
FDA approved the first generic Fosaprepitant Dimeglumine (ANDA) on Jun 9, 2016.
How much does Medicare spend on Fosaprepitant Dimeglumine?
In 2024, Medicare Part D spent $527K on Fosaprepitant Dimeglumine across 2,730 claims for 720 beneficiaries.
How many Fosaprepitant Dimeglumine products are on the market?
The Fosaprepitant Dimeglumine drug market contains 8 NDCs from 7 manufacturers — 8 generic and 0 brand products.
What is the price range for Fosaprepitant Dimeglumine?
NADAC reference prices for Fosaprepitant Dimeglumine range from $38.5080 to $38.5080 per EA.
Which manufacturers make Fosaprepitant Dimeglumine?
7 manufacturers list Fosaprepitant Dimeglumine in NADAC. Ranked by number of NDCs, the largest are Hikma Pharmaceuticals USA Inc. (2), Eugia US LLC (1), Avenacy, LLC (1), NorthStar Rx LLC (1), Baxter Healthcare Corporation (1).